These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

200 related items for PubMed ID: 2007928

  • 1. Prolonged survival in patients with beta-thalassemia major treated with deferoxamine.
    Ehlers KH, Giardina PJ, Lesser ML, Engle MA, Hilgartner MW.
    J Pediatr; 1991 Apr; 118(4 Pt 1):540-5. PubMed ID: 2007928
    [Abstract] [Full Text] [Related]

  • 2. Efficacy of deferoxamine in preventing complications of iron overload in patients with thalassemia major.
    Brittenham GM, Griffith PM, Nienhuis AW, McLaren CE, Young NS, Tucker EE, Allen CJ, Farrell DE, Harris JW.
    N Engl J Med; 1994 Sep 01; 331(9):567-73. PubMed ID: 8047080
    [Abstract] [Full Text] [Related]

  • 3. Consequences and costs of noncompliance with iron chelation therapy in patients with transfusion-dependent thalassemia: a literature review.
    Delea TE, Edelsberg J, Sofrygin O, Thomas SK, Baladi JF, Phatak PD, Coates TD.
    Transfusion; 2007 Oct 01; 47(10):1919-29. PubMed ID: 17880620
    [Abstract] [Full Text] [Related]

  • 4. Chelation therapy in beta-thalassemia major. III. The role of splenectomy in achieving iron balance.
    Graziano JH, Piomelli S, Hilgartner M, Giardina P, Karpatkin M, Andrew M, LoIacono N, Seaman C.
    J Pediatr; 1981 Nov 01; 99(5):695-9. PubMed ID: 7299540
    [Abstract] [Full Text] [Related]

  • 5. Improving survival with deferiprone treatment in patients with thalassemia major: a prospective multicenter randomised clinical trial under the auspices of the Italian Society for Thalassemia and Hemoglobinopathies.
    Maggio A, Vitrano A, Capra M, Cuccia L, Gagliardotto F, Filosa A, Magnano C, Rizzo M, Caruso V, Gerardi C, Argento C, Campisi S, Cantella F, Commendatore F, D'Ascola DG, Fidone C, Ciancio A, Galati MC, Giuffrida G, Cingari R, Giugno G, Lombardo T, Prossomariti L, Malizia R, Meo A, Roccamo G, Romeo MA, Violi P, Cianciulli P, Rigano P.
    Blood Cells Mol Dis; 2009 Nov 01; 42(3):247-51. PubMed ID: 19233692
    [Abstract] [Full Text] [Related]

  • 6. Survival and complications in patients with thalassemia major treated with transfusion and deferoxamine.
    Borgna-Pignatti C, Rugolotto S, De Stefano P, Zhao H, Cappellini MD, Del Vecchio GC, Romeo MA, Forni GL, Gamberini MR, Ghilardi R, Piga A, Cnaan A.
    Haematologica; 2004 Oct 01; 89(10):1187-93. PubMed ID: 15477202
    [Abstract] [Full Text] [Related]

  • 7. Incidence of ototoxicity in pediatric patients with transfusion-dependent thalassemia who are less well-chelated by mono- and combined therapy of iron chelating agents.
    Tanphaichitr A, Kusuwan T, Limviriyakul S, Atipas S, Pooliam J, Sangpraypan T, Tanphaichitr VS, Viprakasit V.
    Hemoglobin; 2014 Oct 01; 38(5):345-50. PubMed ID: 25051423
    [Abstract] [Full Text] [Related]

  • 8. A new era in iron chelation therapy: the design of optimal, individually adjusted iron chelation therapies for the complete removal of iron overload in thalassemia and other chronically transfused patients.
    Kontoghiorghes GJ.
    Hemoglobin; 2009 Oct 01; 33(5):332-8. PubMed ID: 19814679
    [Abstract] [Full Text] [Related]

  • 9. A moderate transfusion regimen may reduce iron loading in beta-thalassemia major without producing excessive expansion of erythropoiesis.
    Cazzola M, Borgna-Pignatti C, Locatelli F, Ponchio L, Beguin Y, De Stefano P.
    Transfusion; 1997 Feb 01; 37(2):135-40. PubMed ID: 9051086
    [Abstract] [Full Text] [Related]

  • 10. Sustained normalization of cardiac function by chelation therapy in thalassaemia major.
    Freeman AP, Giles RW, Berdoukas VA, Talley PA, Murray IP.
    Clin Lab Haematol; 1989 Feb 01; 11(4):299-307. PubMed ID: 2605872
    [Abstract] [Full Text] [Related]

  • 11. Combined therapy with desferrioxamine and deferiprone in beta thalassemia major patients with transfusional iron overload.
    Daar S, Pathare AV.
    Ann Hematol; 2006 May 01; 85(5):315-9. PubMed ID: 16450126
    [Abstract] [Full Text] [Related]

  • 12. Outcomes, utilization, and costs among thalassemia and sickle cell disease patients receiving deferoxamine therapy in the United States.
    Delea TE, Hagiwara M, Thomas SK, Baladi JF, Phatak PD, Coates TD.
    Am J Hematol; 2008 Apr 01; 83(4):263-70. PubMed ID: 17924547
    [Abstract] [Full Text] [Related]

  • 13. Iron chelation in thalassemia: combined or monotherapy? The Egyptian experience.
    El-Beshlawy A, Manz C, Naja M, Eltagui M, Tarabishi C, Youssry I, Sobh H, Hamdy M, Sharaf I, Mostafa A, Shaker O, Hoffbrand AV, Taher A.
    Ann Hematol; 2008 Jul 01; 87(7):545-50. PubMed ID: 18351337
    [Abstract] [Full Text] [Related]

  • 14. Intensive iron chelation therapy in beta-thalassemia major: some effects on iron metabolism and blood transfusion dependence.
    Silvestroni E, Bianco I, Graziani B, Lerone M, Valente M, Congedo P, Ponzini D, Costantini S.
    Acta Haematol; 1982 Jul 01; 68(2):115-23. PubMed ID: 6812366
    [Abstract] [Full Text] [Related]

  • 15. Cooley anemia: high transfusion regimen and chelation therapy, results, and perspective.
    Weiner M, Karpatkin M, Hart D, Seaman C, Vora SK, Henry WL, Piomelli S.
    J Pediatr; 1978 Apr 01; 92(4):653-8. PubMed ID: 633033
    [No Abstract] [Full Text] [Related]

  • 16. A prospective evaluation of iron chelation therapy in children with severe beta-thalassemia. A six-year study.
    Maurer HS, Lloyd-Still JD, Ingrisano C, Gonzalez-Crussi F, Honig GR.
    Am J Dis Child; 1988 Mar 01; 142(3):287-92. PubMed ID: 3344715
    [Abstract] [Full Text] [Related]

  • 17. Iron chelation therapy with deferoxamine in Cooley anemia.
    Cohen A, Schwartz E.
    J Pediatr; 1978 Apr 01; 92(4):643-7. PubMed ID: 633031
    [Abstract] [Full Text] [Related]

  • 18. Comparison of oral and subcutaneous iron chelation therapies in the prevention of major endocrinopathies in beta-thalassemia major patients.
    Wang CH, Wu KH, Tsai FJ, Peng CT, Tsai CH.
    Hemoglobin; 2006 Apr 01; 30(2):257-62. PubMed ID: 16798651
    [Abstract] [Full Text] [Related]

  • 19. Chelation therapy, transfusion requirement, and iron balance in young thalassemic patients.
    Piomelli S, Graziano J, Karpatkin M, Dudell GG, Hart D, Hilgartner M, Khanna K, Valdes-Cruz LM, Vora S.
    Ann N Y Acad Sci; 1980 Apr 01; 344():409-17. PubMed ID: 6930881
    [No Abstract] [Full Text] [Related]

  • 20. Combination of deferasirox and deferoxamine in clinical practice: an alternative scheme of chelation in thalassemia major patients.
    Cassinerio E, Orofino N, Roghi A, Duca L, Poggiali E, Fraquelli M, Zanaboni L, Cappellini MD.
    Blood Cells Mol Dis; 2014 Sep 01; 53(3):164-7. PubMed ID: 24846580
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 10.